Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Improving response to immune checkpoint blockade in cSCC

Paolo Bossi, MD, University of Brescia, Brescia, Italy, reflects on ongoing treatment approaches currently under investigation in patients with cutaneous squamous cell carcinoma, including the role of combined systemic immunotherapy and intra-tumoral injection of a modified herpes-simplex virus with the intention to improve response to immune checkpoint blockade. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.